Equities analysts predict that Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) will announce earnings of ($0.07) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Ohr Pharmaceuticals’ earnings. Ohr Pharmaceuticals posted earnings of ($0.21) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 66.7%. The firm is expected to report its next quarterly earnings results on Thursday, December 28th.

According to Zacks, analysts expect that Ohr Pharmaceuticals will report full-year earnings of ($0.74) per share for the current financial year, with EPS estimates ranging from ($0.95) to ($0.53). For the next year, analysts anticipate that the business will post earnings of ($1.12) per share, with EPS estimates ranging from ($1.55) to ($0.68). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Ohr Pharmaceuticals.

Ohr Pharmaceuticals (NASDAQ:OHRP) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.18.

OHRP has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Ohr Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $0.75 price objective on the stock in a report on Saturday, August 19th. HC Wainwright set a $10.00 price objective on shares of Ohr Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 16th.

Shares of Ohr Pharmaceuticals (NASDAQ:OHRP) traded down 1.8629% on Tuesday, hitting $0.7744. 171,972 shares of the company traded hands. Ohr Pharmaceuticals has a 1-year low of $0.56 and a 1-year high of $4.05. The firm’s 50-day moving average is $0.68 and its 200 day moving average is $0.70. The firm’s market capitalization is $43.53 million.

Several institutional investors and hedge funds have recently bought and sold shares of OHRP. Cannell Peter B & Co. Inc. acquired a new position in Ohr Pharmaceuticals in the 2nd quarter worth approximately $187,000. Renaissance Technologies LLC increased its holdings in Ohr Pharmaceuticals by 242.3% in the 1st quarter. Renaissance Technologies LLC now owns 229,709 shares of the biotechnology company’s stock worth $191,000 after buying an additional 162,600 shares during the period. Vanguard Group Inc. increased its holdings in Ohr Pharmaceuticals by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock worth $520,000 after buying an additional 5,481 shares during the period. Finally, Sabby Management LLC increased its holdings in Ohr Pharmaceuticals by 30.5% in the 1st quarter. Sabby Management LLC now owns 1,509,315 shares of the biotechnology company’s stock worth $1,253,000 after buying an additional 352,922 shares during the period. Hedge funds and other institutional investors own 7.02% of the company’s stock.

WARNING: “Brokerages Anticipate Ohr Pharmaceuticals, Inc. (OHRP) to Post -$0.07 Earnings Per Share” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/12/brokerages-anticipate-ohr-pharmaceuticals-inc-ohrp-to-post-0-07-earnings-per-share.html.

About Ohr Pharmaceuticals

OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

Get a free copy of the Zacks research report on Ohr Pharmaceuticals (OHRP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.